Who Paid My Doc
Relizorb
Device Gastroenterology
General payments
$438,721
Research payments
$806,802
Through program year 2022, $438,721 in general payments and $806,802 in research payments were reported against Relizorb (Gastroenterology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2022 | Research | $624,668 | 1 |
| 2021 | General | $132,840 | 39 |
| 2021 | Research | $182,134 | 4 |
| 2020 | General | $84,543 | 45 |
| 2019 | General | $221,338 | 261 |
Breakdown
The top 5 of 23 recipients; each share is of general payments naming this product in 2021.
The top 5 of 15 specialties; each share is of general payments naming this product to practitioners with a specialty in 2021. Each practitioner is counted under their primary specialty.
The top 5 of 12 states; each share is of general payments naming this product in 2021 where a state was reported.
Records
345 general · 5 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.